A Placebo- and Active-Controlled Assessment of 6- and 50-mg Oral Doxepin on Cardiac Repolarization in Healthy Volunteers: A Thorough QT Evaluation

Clinical Therapeutics

Volumn 33, Issue 7, 2011, Pages 851-862

  Mansbach, Robert S ^a   Ludington, Elizabeth ^b   Rogowski, Roberta ^c   Kittrelle, Jeffrey P ^d   Jochelson, Philip ^e  

^a Private Practice   (United States)

^b Synteract   (United States)

^c Somaxon Pharmaceuticals   (United States)

^d Specialty Pharma Consulting Inc   (United States)

^e MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

Doxepin; Insomnia; Moxifloxacin; Nordoxepin; Thorough QT study

Indexed keywords

DOXEPIN; MOXIFLOXACIN; NORDOXEPIN; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREATHING RATE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HEART RATE; HEART REPOLARIZATION; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PULSE RATE; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS INFECTION;

ADMINISTRATION, ORAL; ADULT; AZA COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DOXEPIN; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; LONG QT SYNDROME; MALE; QUINOLINES; YOUNG ADULT;

EID: 79960282682     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.05.092     Document Type: Article

References (35)

1. Roth T., Durrence H., Jochelson P., et al. Efficacy and safety of doxepin 6 mg in a model of transient Insomnia. Sleep Med 2010, 11:843-847.
2. Roth T., Rogowski R., Hull S., et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007, 30:1555-1561.
3. Krystal A.D., Durrence H.H., Scharf M., et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2011, 33:1553-1561.
4. Baldessarini R.J. Drugs used in the treatment of psychiatric disorders. Goodman & Gillman's The Pharmacological Basis of Therapeutics 1996, 431-459. McGraw-Hill, New York. 9th ed. J.G. Hardman, A.G. Gilman, L.E. Limbird (Eds.).
5. Cusack B., Nelson A., Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 1994, 114:559-565.
6. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997, 340:249-258.
7. Goodnick P., Jerry J., Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother 2002, 3:479-498.
8. Pinder R.M., Brogden R.N., Speight T.M., Avery G.S. Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 1977, 13:161-218.
9. The clinical evaluation of QT/QTc interval prolongation and proarrythmic potential for non-antiarrhythmic drugs International Conference on Harmonisation, Accessed March 8, 2011. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/Step4/E14_Guideline.pdf.
10. Baker B., Dorian P., Sandor P., et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 1997, 17:15-21.
11. Veith R.C., Raskind M.A., Caldwell J.H., et al. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. N Engl J Med 1982, 306:954-959.
12. Giardina E.G., Cooper T.B., Suckow R., Saroff A.L. Cardiovascular effects of doxepin in cardiac patients with ventricular arrhythmias. Clin Pharmacol Ther 1987, 42:20-27.
13. Rodriguez de la Torre B., Dreher J., Malvany I., et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Thera Drug Monit 2001, 23:435-440.
14. Ahles S., Gwirtsman H., Halaris A., et al. Comparative cardiac effects of maprotiline and doxepin in elderly depressed patients. J Clin Psychiatry 1984, 45:460-465.
15. Vohra J., Burrows G., Sloman G. Assessment of cardiovascular side effects of therapeutic doses of tricyclic anti-depressant drugs. Aust N Z J Med 1975, 5:7-11.
16. Nair N.P., Amin M., Schwartz G., et al. A comparison of the cardiac safety and therapeutic efficacy of trimipramine versus doxepin in depressed geriatric patients. J Am Geriatr Soc 1993, 41:863-867.
17. Biggs J.T., Preskorn S.H., Ziegler V.E., et al. Dosage schedule and plasma levels of doxepin and desmethyldoxepin. J Clin Psychiatry 1978, 39:740-742.
18. Green D.O. Clinical importance of doxepin antidepressant plasma levels. J Clin Psychiatry 1978, 39:481-482.
19. Faulkner R., Pitts W., Lee C., et al. Multiple-dose doxepin kinetics in depressed patients. Clin Pharmacol Ther 1983, 34:509-515.
20. Bloomfield D.M., Kost J.T., Ghosh K., et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 2008, 84:475-480.
21. Donado E., Izquierdo I., Pérez I., et al. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a thorough QT/QTc study' performed according to ICH guidelines. Br J Clin Pharmacol 2010, 69:401-410.
22. Morganroth J., Lepor H., Hill L.A., et al. Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study. Clin Pharmacol Ther 2010, 87:609-613.
23. Agin M.A., Kazierad D.J., Abel R., et al. Assessing QT variability in healthy volunteers. In: Thirty-second annual ACCP meeting abstracts. J Clin Pharmacol 2003, 43:1016-1040.
24. Scharf M., Rogowski R., Hull S., et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008, 69:1557-1564.
25. Sala M., Coppa F., Cappucciati C., et al. Antidepressants: their effects on cardiac channels, QT prolongation and torsade de pointes. Curr Opinion Invest Drugs 2006, 7:256-263.
26. Soldovieri M.V., Miceli F., Taglialatela M. Cardiotoxic effects of antihistamines: from basics to clinics (and back). Chem Res Toxicol 2008, 21:997-1004.
27. Roy M., Dumaine R., Brown A.M. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996, 94:817-823.
28. Aslanian R., Piwinski J.J., Zhu X., et al. Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett 2009, 19:5043-5047.
29. Duncan R.S., McPate M.J., Ridley J.M., et al. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochemical Pharmacol 2007, 74:425-437.
30. Harrigan R.A., Brady W.J. ECG abnormalities in tricyclic antidepressant ingestion. Am J Emerg Med 1999, 17:387-393.
31. Alter P., Tontsch D., Grimm W. Doxepin-induced torsade de pointes tachycardia. Ann Intern Med 2001, 135:384-385.
32. Virtanen R., Scheinin M., Iisalo E. Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharmacologica Toxicologica 1980, 47:371-376.
33. Virtanen R., Iisalo E., Irjala K. Protein binding of doxepin and desmethyldoxepin. Acta Pharmacol Toxicol (Copenh) 1982, 51:159-164.
34. Redfern W.S., Carlsson L., Davis A.S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovas Res 2003, 58:32-45.
35. Leucht S., Steimer W., Kreuz S., et al. Doxepin plasma concentrations: is there really a therapeutic range?. J Clin Psychopharmacol 2001, 21:432-439.